cancer
-
Telormedix’s TMX-101 exhibits high safety in phase I/II for non-muscle invasive bladder cancer
Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.
cancer | 04 May 2012
-
Espicom predicts new novel approaches to the treatment of cancer will be launched by 2018
According to an Espicom report, Targeted Cancer D: The launch landscape to 2018,the global cancer market could be set for rapid growth in key sectors, driven by increasingly un-met clinical need and the introduction of new drugs which effectively target new pathways.
cancer | 29 March 2012
-
apceth, Indivumed to develop biomarker platform for targeted cellular therapies
apceth and Indivumed have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
cancer | 27 March 2012
-
ArQule announces tivantinib meets primary endpoint
ArQule announces tivantinib meets primary endpoint, significantly extending time to progression in Phase 2 trial in second-line hepatocellular carcinoma.
cancer | 13 March 2012
-
Ziopharm Oncology presents preclinical data for Darinaparsin at AACR-NCI-EORTC meeting
Ziopharm Oncology announced that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In addition to company authors, the studies included authors Joseph R Bertino MD and Nitu Bansal PhD from UMDNJ-The Cancer Institute of New Jersey.
cancer | 23 November 2011
-
Plexxikon novel agents aim to address cancer treatment in new ways
Plexxikon announced scientific findings from two key programs in its oncology pipeline. First, findings from preclinical studies showed that treatment with a novel oral agent, PLX3397, re-programmed the tumor microenvironment, supporting further development of this single agent treatment for certain cancers and malignancies such as prostate cancer. In another presentation, Plexxikon researchers characterized the discovery of next generation BRAF inhibitors based on a preclinical model showing that these new inhibitors avoided the drug-induced skin lesions (cutaneous squamous cell carcinoma) observed with other BRAF inhibitors.
cancer | 21 November 2011
-
Telormedix announces promising TMX-202 preclinical results for skin cancer treatment
Telormedix announced that it has achieved significant preclinical results for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer. The recent preclinical study evaluated TMX-202 as a topical skin cancer treatment in a mouse skin cancer model and showed that it had both better efficacy and better tolerability than the current gold standard treatment for skin cancer, Imiquimod/Aldara.
cancer | 15 November 2011
-
Telormedix announces promising TMX-202 preclinical results for skin cancer treatment
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, announced that it has achieved significant preclinical results for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer.
cancer | 10 November 2011
-
Phase 3 trial of Regorafenib in metastatic colorectal cancer meets primary endpoint of improving overall survival
Bayer HealthCare announced positive results from its Phase 3 trial evaluating its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
cancer | 31 October 2011
-
BioAlliance Pharma presents orphan drug survival results at international liver cancer congress
BioAlliance Pharma SA announces oral communication of the phase 2 clinical trial results of its orphan product Livatag at the annual congress of ILCA (International Liver Cancer Association). Prof Philippe Merle, Professor of hepatology at the Hos…
cancer | 06 September 2011
